<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>During the past four decades, a substantial progress has been made in the field of hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>From July, 2007 to December, 2010, a transplant survey from 42 HSCT units indicates that the types of transplantation performed are related identical (43%), related mismatched/haploidentical (28%), unrelated donor matched (11%), unrelated donor mismatched (7%), umbilical cord blood (UCB, 2%) and autologous (9%) </plain></SENT>
<SENT sid="2" pm="."><plain>The distribution of disease entities being transplanted in allogeneic settings is <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (34%), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>(ALL) (24%), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) (20%), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (8%), <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) (7%), Mediterranean <z:hpo ids='HP_0001903'>anemia</z:hpo> (MIA) (2%), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) (3%), and other diseases (3%) </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical data from Peking University Institute of Hematology and other transplant centers suggest that haploidentical transplantation has been a choice of the best alternative source of stem cells for individual patients without matched sibling donors </plain></SENT>
<SENT sid="4" pm="."><plain>A modified donor lymphocyte infusion (DLI) approach can be safely used for prophylaxis and treatment of <z:hpo ids='HP_0001909'>leukemia</z:hpo> relapse in patients with advanced <z:hpo ids='HP_0001909'>leukemia</z:hpo> following mismatched transplant </plain></SENT>
<SENT sid="5" pm="."><plain>The number of transplants from unrelated donor or related mismatched/haploidentical donor has increased significantly during recent years </plain></SENT>
<SENT sid="6" pm="."><plain>Double UCBT is a promising strategy for the therapy of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, mesenchymal stem cell (MSC) transplantation may be a potential therapeutic approach for treating <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) </plain></SENT>
</text></document>